We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hutchison China Meditech Ltd | LSE:0J7G | London | Ordinary Share | HUTCHISON CHINA MEDITECH ADR REPRESENTIN |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| 0.00 | 0.00% | 33.29 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 138 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 838M | 100.78M | - | N/A | 0 |
| Date | Time | Source | Headline |
|---|---|---|---|
| 11/1/2024 | 07:00 | RNSNON | Hutchmed (China) Limited Sovleplenib NDA Granted Priority Review in China |
| 29/12/2023 | 08:30 | UKREG | Hutchmed (China) Limited Blocklisting Six Monthly Return |
| 29/12/2023 | 08:30 | UKREG | Hutchmed (China) Limited Total Voting Rights |
| 21/12/2023 | 10:00 | UKREG | Hutchmed (China) Limited Overseas Regulatory Announcement |
| 13/12/2023 | 07:00 | RNSNON | Hutchmed (China) Limited Completed Enrollment of Phase II/III Trial |
| 07/12/2023 | 10:04 | UKREG | Hutchmed (China) Limited Overseas Regulatory Announcement |
| 01/12/2023 | 07:00 | RNSNON | Hutchmed (China) Limited Clinical Data to be Presented at Congresses |
| 30/11/2023 | 08:30 | UKREG | Hutchmed (China) Limited Total Voting Rights |
| 09/11/2023 | 07:00 | UKREG | Hutchmed (China) Limited U.S. FDA Approval of FRUZAQLA(TM) (fruquintinib) |
| 24/10/2023 | 09:30 | UKREG | Hutchmed (China) Limited Vesting of awards under the LTIP |
1 Year Hutchison China Meditech Chart |
Intraday Hutchison China Meditech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
